These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18388340)

  • 21. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
    Lancet; 2000 Jan; 355(9201):337-45. PubMed ID: 10665552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.
    Toyoda K; Okada Y; Minematsu K; Kamouchi M; Fujimoto S; Ibayashi S; Inoue T
    Neurology; 2005 Oct; 65(7):1000-4. PubMed ID: 16217049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical value of protoparaxotril saporlirs combined with aspirin in the secondary prevention of cerebral infarction].
    Zhou BR; Xu ZQ; Liu ZF
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Sep; 28(9):797-800. PubMed ID: 19065892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    Diener HC; Sacco RL; Easton JD; Granger CB; Bernstein RA; Uchiyama S; Kreuzer J; Cronin L; Cotton D; Grauer C; Brueckmann M; Chernyatina M; Donnan G; Ferro JM; Grond M; Kallmünzer B; Krupinski J; Lee BC; Lemmens R; Masjuan J; Odinak M; Saver JL; Schellinger PD; Toni D; Toyoda K;
    N Engl J Med; 2019 May; 380(20):1906-1917. PubMed ID: 31091372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
    Ng FH; Tunggal P; Chu WM; Lam KF; Li A; Chan K; Lau YK; Kng C; Keung KK; Kwan A; Wong BC
    Am J Gastroenterol; 2012 Mar; 107(3):389-96. PubMed ID: 22108447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
    Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S;
    Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].
    Hennerici MG; Meairs S
    Nervenarzt; 1995 Dec; 66(12):890-4; discussion 885. PubMed ID: 8584072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
    Ann Neurol; 1997 Dec; 42(6):857-65. PubMed ID: 9403477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia].
    Hartmann A
    Nervenarzt; 1995 Dec; 66(12):886-9; discussion 885. PubMed ID: 8584071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ;
    Lancet; 2004 Jul 24-30; 364(9431):331-7. PubMed ID: 15276392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
    Lee CW; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Han S; Lee SG; Seong IW; Rha SW; Jeong MH; Lim DS; Yoon JH; Hur SH; Choi YS; Yang JY; Lee NH; Kim HS; Lee BK; Kim KS; Lee SU; Chae JK; Cheong SS; Suh IW; Park HS; Nah DY; Jeon DS; Seung KB; Lee K; Jang JS; Park SJ
    Circulation; 2014 Jan; 129(3):304-12. PubMed ID: 24097439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
    Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
    Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    Schulz-Schüpke S; Byrne RA; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tölg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Mudra H; von Hodenberg E; Wöhrle J; Angiolillo DJ; von Merzljak B; Rifatov N; Kufner S; Morath T; Feuchtenberger A; Ibrahim T; Janssen PW; Valina C; Li Y; Desmet W; Abdel-Wahab M; Tiroch K; Hengstenberg C; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Schömig A; Mehilli J; Kastrati A;
    Eur Heart J; 2015 May; 36(20):1252-63. PubMed ID: 25616646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
    Vetrano A; Milani M; Corsini G
    G Ital Cardiol; 1999 May; 29(5):524-8. PubMed ID: 10367219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
    Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.